OncoHost Announces Interim Results From PROPHETIC Trial, Multicenter Assessment Of NSCLC Patient Response To Immunotherapy
Original source here
With One Blood Test Pre-Treatment, PROphet® Provides Response Probability for the First Year of Treatment, Plus Analysis of Resistance Associated Pathways for NSCLC Patients
OncoHost, a global leader in next-generation precision oncology for improved personalized cancer therapy, announced results from its ongoing multicenter clinical trial, PROPHETIC. These interim results confirm that through proteomic analysis of just one blood test before treatment, OncoHost’s AI platform, PROphet®, can predict response to cancer treatment for non-small cell lung cancer (NSCLC) patients with remarkably high accuracy at three months, six months and one year.
“These results are statistically and clinically significant, giving us great hope for the future of precision oncology. The value that this validation will provide, both to cancer patients and their clinicians, is insurmountable,” said Dr. Ofer Sharon, CEO of OncoHost. “With just one blood test pre-treatment, we will now be empowered with a level of knowledge that is currently non-existent. Understanding the response probability trajectory for a full twelve months before treatment initiation, combined with insights on resistance associated pathways and proteins, has the potential to allow physicians to make critical clinical decisions earlier, all based on personalized patient data.”
PROphet® is a first-of-its-kind diagnostic platform that combines proteomic analysis with AI to predict patient response to immunotherapy and identify resistance associated processes with just one blood test pre-treatment. The device employs high-throughput protein analysis technology, scanning approximately 7,000 proteins in a patient’s plasma using the SomaScan® platform by SomaLogic (Nasdaq: SLGC), combined with proprietary bioinformatic and machine learning-based algorithms, to identify proteomic patterns that are predictive of patient outcome. PROphet® also identifies potential drug targets, advancing the development of novel therapeutic strategies and providing clinicians with potential combination strategies to overcome treatment resistance.
With a focus on patients diagnosed with advanced stages of melanoma or non-small cell lung cancer (NSCLC) receiving immunotherapy, OncoHost’s clinical trials have shown PROphet® to have high accuracy. OncoHost continues to open additional clinical trial sites around the world and will be expanding its research to further cancer indications including ovarian cancer, head and neck cancers and urogenital cancers.
The full results of the analysis will be published later this year in a peer-reviewed paper. This announcement comes ahead of OncoHost’s official launch of PROphet® in 2022.